Ebixa en es it fr

Ebixa Brand names, Ebixa Analogs

Ebixa Brand Names Mixture

  • No information avaliable

Ebixa Chemical_Formula


Ebixa RX_link


Ebixa fda sheet

Ebixa FDA

Ebixa msds (material safety sheet)

Ebixa MSDS

Ebixa Synthesis Reference

No information avaliable

Ebixa Molecular Weight

179.302 g/mol

Ebixa Melting Point

258 oC (HCl salt)

Ebixa H2O Solubility

35 mg/mL (HCl salt), 0.9 mg/mL for free base

Ebixa State


Ebixa LogP


Ebixa Dosage Forms


Ebixa Indication

For the treatment of moderate to severe dementia of the Alzheimer's type.

Ebixa Pharmacology

Memantine, an amantadine derivative, is an NMDA receptor antagonist used in the treatment of Alzheimer's disease. It differs from traditional agents used in Alzheimer's disease by acting on glutamatergic neurotransmission, rather than cholinergic. There is some evidence that dysfunction of glutamatergic neurotransmission, manifested as neuronal excitotoxicity, is involved in the aetiology of Alzheimer's disease (Cacabelos et al., 1999). As such, targeting the glutamatergic system, specifically NMDA receptors, was a novel approach to treatment in view of the limited efficacy of existing drugs targeting the cholinergic system. A systematic review of randomised controlled trials found that memantine has a positive effect on cognition, mood, behaviour, and the ability to perform daily activities. There is no evidence that memantine prevents or slows neurodegeneration in patients with Alzheimer's disease.

Ebixa Absorption

Well absorbed orally with a bioavailability of approximately 100%. Peak plasma concentrations are reached in 3-7 hours. Food has no effect on absorption.

Ebixa side effects and Toxicity

Side effects include pain, abnormal crying, leg pain, fever, increased apetite. Adverse drug reactions include: dizziness, confusion, headache, hallucinations, tiredness. Less common side effects include: vomiting, anxiety, hypertonia, cystitis, and increased libido. Doses of up to 400 mg have been tolerated.

Ebixa Patient Information

Information for Patients and Caregivers: Caregivers should be instructed in the recommended administration (twice per day for doses above 5 mg) and dose escalation (minimum interval of one week between dose increases).

Ebixa Organisms Affected

Humans and other mammals